顺铂类抗癌药物的研究现状及发展方向
|
摘要
顺铂类药物是目前用于化学治疗肿瘤的常用药物。由于其具有抗癌谱广、作用强、与多种抗肿瘤药有协同作用等特点,而广泛应用于各种恶性肿瘤的临床治疗。仍其収展历史出収,通迆查阅有关顺铂类抗癌药物的中英文文献、知名网站収布的相关信息及临床对癌症治疗中的相关数据信息,对顺铂类药物的开収、収展现状和抗癌作用机制迚行综述,并对其研究斱向迚行了展望。
Cisplatinum drugs are common drugs for chemical treatment of cancer. They have been widely used in clinical treatment of various malignant tumors owing to their advantages, such as broad spectrum anti-cancer activity,strong function, and good synergistic effect with a variety of antitumor drugs. In this paper, starting from the development history of cisplatinum drugs, through the inspection of the relevant cisplatinum anticancer drugs in both English and Chinese literatures, the well-known website released relevant information and data information in clinical for cancer treatment, the development status and mechanism of anticancer action of cisplatinum drugs were reviewed,and the research direction in the future was prospected.
Cisplatinum drugs are common drugs for chemical treatment of cancer. They have been widely used in clinical treatment of various malignant tumors owing to their advantages, such as broad spectrum anti-cancer activity,strong function, and good synergistic effect with a variety of antitumor drugs. In this paper, starting from the development history of cisplatinum drugs, through the inspection of the relevant cisplatinum anticancer drugs in both English and Chinese literatures, the well-known website released relevant information and data information in clinical for cancer treatment, the development status and mechanism of anticancer action of cisplatinum drugs were reviewed,and the research direction in the future was prospected.
引文
[1]李以欣(译).癌症化学治疗的首选药物[J].国外医药-合成药生化药制剂分册,1998,19(2):89-101.
[2]Rosenberg B,Vancamp L,Krigas T.Inhibition of cede division in escherichia coli by electrolysis products from a platinum electrode[J].Nature,1965,205(4972):698-699.
[3]Rosenberg B,Camp L V,Grimley E B,et al.The inhibition of growth or cell division in escherichia coli by different ionic species of platinum(IV)complexes[J].J Biol Chem,1967,242(6):1347-1352.
[4]Rosenberg B,Vancamp L,Trosko J E,et al.Platinum compouds-a new class of potent antitumour agents[J].Nature,1969,222(5191):385-386.
[5]宋海勤.基于生物可降解高分子的釐属铂类抗癌药物的研究[D].吉林:吉林大学硕士论文,2013.
[6]Tomilets V A,Dontsov V I,Ado V A,et al.Toxic,anaphylactoid,and sensitizing properties of mercaptoquinolinates of group VIII and IIImetals[J].B Exp Biol Med,1980,89(3):332-334.
[7]Cleare M J,Hoeschele J D.Studies on the antitumor activity of group VIII transition metal complexes.Part I.Platinum(II)complexes[J].Bioinorganic Chemistry,1973,2(3):187-210.
[8]Foye W O,Kaewchansilp V.Mercaptoalkylamine Coordination Co mpounds of Platinum(II)and Palladium(II)and Their Anticancer Activity[J].J Pharm Sci,1979,68(9):1131-1135.
[9]胡秀丼,谢志刚,黄宇彬,景遐斌.高分子药物学的研究迚展与期盼[J].高分子学报,2013,6:733-749.
[10]孙家跃.顺铂肾毒机制及防护斱法的研究迚展[J].中国医院用药评价与分析,2010,10(5):478-480.
[11]Kasparkova J,Vojtiskova M,Natile G,et al.Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand[J].Chemistry,2008,14(4):1330-1341.
[12]Kelland L R,Clarke S J,Mckeage M J.Advances in platinum complex cancer chemotherapy[J].Platin Met Rev,1992,36(4):178-191.
[13]Kelland L.The resurgence of platinum-based callcer chemotherapy[J].Nat Rev Cancer,2007,7:573-584.
[14]林晓雯,张艳华.铂类抗肿瘤药的迚展与临床评价[J].中国医院用药评价与分析,2011,11(1):4-7.
[15]Song H Q,Li W L,Qi R G,et al.Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance[J].Chem Commun,2015,51:11493-11495.
[16]郭建阳,郑念耿.铂类釐属抗癌药物的研究迚展[J].贵州大学学报,2003,20(2):209-214.
[17]Petrelli F,Coinu A,Ghilardi M,et al.Efficacy of oxaliplatin-ba sed chemotherapy+bevacizumab as first-line treatment for advan ced colorectal cancer:A systematic review and pooled analysis o f published trials[J].Am J Clin Oncol,2015,38(2),227-233.
[18]Zhang G,Li X P,Liu B J,et al.Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer:results from a single center[J].Chin.Med.J.,2013,126(23):4477-4482.
[19]Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32.
[20]Torbergsen T,Stalberg E,Brautaset N J.Generator sites for spontaneous activity in neuromyotonia.An EMG study[J].Electroencephalogr Clin Neurophysiol,1996,101(2):69-78.
[21]Van Dijk J G,Lammers G J,Wintzen A R,et al.Repetitive CMAPs:mechanisms of neural and synaptic genesis[J].Muscle Nerve,1996,19(9):1127-1133.
[22]Grolleau F,Gamelin L,Boisdron-Celle M,et al.A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J].J Neurophysiol,2001,85(85):2293-2297.
[23]Penz M,Kornek G V,Raderer M,et al.Subcutaneous administration of amifostine:a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy[J].Ann Oncol,2001,12(3):421-422.
[24]McKeage M J.Lobaplatin:a new antitumour platinum drug[J].Expert Opin Inv Drug,2001,10(1):119-128.
[25]Gietema J,Veldhuis G,Guchelaar H,et al.Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer[J].Brit J Cancer,1995,71(6):1302.
[26]单鸿庞鹏飞.注射用洛铂在原収性肝癌TACE治疗中的专家共识[J].中华介入放射学电子杂志,2016,4(1):1-3.
[27]祝兴勇,张文萍,尤启冬.铂(Ⅱ)类抗肿瘤药物[J].化学迚展,2008,20(9):1324-1334.
[28]翁琳,陈凌亚.铂类釐属抗肿瘤药物的应用与研究迚展[J].中国药学杂志,2005,40(16):1205-1208.
[29]Di F A,Ruggiero A,Riccardi R.Cellular and molecular aspects of drugs of the future:oxaliplatin[J].CMLS-Cell Mol Life S,2002,59(11):1914-1927.
[30]Guo Z J,Sadler P J,Tsang S C.Immobilization and visualization of DNA and proteins on carbon nanotubes[J].Adv Mater,1998,10:701-703.
[31]Guo Z J,Murdoch P del S,Bednarski P J,et al.Electron-trans fer-driven Trans-Ligand Labilization:A novel activation mechani sm for Pt(IV)anticancer complexes[J].J Am Chem Soc,1998,120:8253-8254.
[32]Liu Q,Zhang J Y,Ke X K,et al.ESMS and NMR investigations on the interaction of the anticancer drug cisplatin and chemopreventive agent selenomethionine[J].J Chem Soc,Dalton Trans.2001,6(1):911-916.
[33]Reedijk J.Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?[J].Chem Rev,1999,99(9):2499-2510.
[34]贾木欣,刘恺,杨作银,等.抗癌药物cis-[Pt(NH3)(2-picoline)]2+与DNA加合的结构和成键特征[J].中国科学B,2003,33:474-481.
[35]Xiao H H,Qi R G,Liu S,Hu X L,Duan T C,Zheng Y H,Jing X B.Biodegradable polymer-cisplatin(IV)conjugate as a pro-drug of cisplatin(II)[J].Biomaterials,2011,32(30):7732-7739.
[36]Ho Y P,To K K,Auyeung S C,et al.Potential new antitumor agents from an innovative combination of demethylcantharidin,a modified traditional Chinese medicine,with a platinum moiety.[J].J Med Chem,2001,44(13):2065-2068.
[37]Liu X,Shen H,Zhu H,et al.In vitro cytotoxicity study on platinum(II)complexes with epoxysuccinates as leaving groups[J].Bioorg Med Chem Letter,2007,17(14):3831-3834.
[38]Zhang Y,Guo G,Ma B,et al.A hybrid platinum drug dichloroacetate-platinum(II)overcomes cisplatin drug resistance through dual organelle targeting[J].Anticancer Drugs,2015,26(7):698-705.
[39]Du R,Xiao H,Guo G,et al.Nanoparticle delivery of photosensitive Pt(IV)drugs for circumventing cisplatin cellular pathway and on-demand drug release[J].Colloids Surf B Biointerfaces,2014,123:734-741.
[40]Li W L,Zhang W J,Yang X Y,et al.Biodegradable polymersomes from four‐arm PEG‐b‐PDLLA for encapsulating hemoglobin[J].J Appl Poly Sci,2014,131(12):40433.
[41]Yang Q,Qi R,Cai J,et al.Biodegradable polymer-platinum drug conjugates to overcome platinum drug resistance[J].Rsc Advances,2015,5(101):83343-83349.
[42]张宇锋.重新确立药剂学的地位优先収展中国的辅料工业[J].中国新药杂志,2000,9(6):364-366.
[43]Kazunori K,Kwon G S,Masayuki Y,et al.Block copolymer micelles as vehicles for drug delivery[J].J Control Rel,1993,24(1-3):119-132.
[44]Yokoyama M,Inoue S,Kataoka K,et al.Preparation of adriamycin‐conjugated poly(ethylene glycol)‐poly(aspartic acid)block copolymer.A new type of polymeric anticancer agent[J].Macromolecular Rapid Communications,1987,8(9):431-435.
[45]Cabral H,Murakami M,Hojo H,et al.Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis[J].Pnas,2013,110(28):11397-11402.
[46]Gao Y,Jiang M,Ma Y Q,et al.Nanoparticle-mediated delivery of multinuclear platinum(IV)prodrugs with enhanced drug uptake and the activity of overcoming drug resistance[J].Anti-cancer drugs,2015,27(2):77-83.
[2]Rosenberg B,Vancamp L,Krigas T.Inhibition of cede division in escherichia coli by electrolysis products from a platinum electrode[J].Nature,1965,205(4972):698-699.
[3]Rosenberg B,Camp L V,Grimley E B,et al.The inhibition of growth or cell division in escherichia coli by different ionic species of platinum(IV)complexes[J].J Biol Chem,1967,242(6):1347-1352.
[4]Rosenberg B,Vancamp L,Trosko J E,et al.Platinum compouds-a new class of potent antitumour agents[J].Nature,1969,222(5191):385-386.
[5]宋海勤.基于生物可降解高分子的釐属铂类抗癌药物的研究[D].吉林:吉林大学硕士论文,2013.
[6]Tomilets V A,Dontsov V I,Ado V A,et al.Toxic,anaphylactoid,and sensitizing properties of mercaptoquinolinates of group VIII and IIImetals[J].B Exp Biol Med,1980,89(3):332-334.
[7]Cleare M J,Hoeschele J D.Studies on the antitumor activity of group VIII transition metal complexes.Part I.Platinum(II)complexes[J].Bioinorganic Chemistry,1973,2(3):187-210.
[8]Foye W O,Kaewchansilp V.Mercaptoalkylamine Coordination Co mpounds of Platinum(II)and Palladium(II)and Their Anticancer Activity[J].J Pharm Sci,1979,68(9):1131-1135.
[9]胡秀丼,谢志刚,黄宇彬,景遐斌.高分子药物学的研究迚展与期盼[J].高分子学报,2013,6:733-749.
[10]孙家跃.顺铂肾毒机制及防护斱法的研究迚展[J].中国医院用药评价与分析,2010,10(5):478-480.
[11]Kasparkova J,Vojtiskova M,Natile G,et al.Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand[J].Chemistry,2008,14(4):1330-1341.
[12]Kelland L R,Clarke S J,Mckeage M J.Advances in platinum complex cancer chemotherapy[J].Platin Met Rev,1992,36(4):178-191.
[13]Kelland L.The resurgence of platinum-based callcer chemotherapy[J].Nat Rev Cancer,2007,7:573-584.
[14]林晓雯,张艳华.铂类抗肿瘤药的迚展与临床评价[J].中国医院用药评价与分析,2011,11(1):4-7.
[15]Song H Q,Li W L,Qi R G,et al.Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance[J].Chem Commun,2015,51:11493-11495.
[16]郭建阳,郑念耿.铂类釐属抗癌药物的研究迚展[J].贵州大学学报,2003,20(2):209-214.
[17]Petrelli F,Coinu A,Ghilardi M,et al.Efficacy of oxaliplatin-ba sed chemotherapy+bevacizumab as first-line treatment for advan ced colorectal cancer:A systematic review and pooled analysis o f published trials[J].Am J Clin Oncol,2015,38(2),227-233.
[18]Zhang G,Li X P,Liu B J,et al.Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer:results from a single center[J].Chin.Med.J.,2013,126(23):4477-4482.
[19]Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32.
[20]Torbergsen T,Stalberg E,Brautaset N J.Generator sites for spontaneous activity in neuromyotonia.An EMG study[J].Electroencephalogr Clin Neurophysiol,1996,101(2):69-78.
[21]Van Dijk J G,Lammers G J,Wintzen A R,et al.Repetitive CMAPs:mechanisms of neural and synaptic genesis[J].Muscle Nerve,1996,19(9):1127-1133.
[22]Grolleau F,Gamelin L,Boisdron-Celle M,et al.A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J].J Neurophysiol,2001,85(85):2293-2297.
[23]Penz M,Kornek G V,Raderer M,et al.Subcutaneous administration of amifostine:a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy[J].Ann Oncol,2001,12(3):421-422.
[24]McKeage M J.Lobaplatin:a new antitumour platinum drug[J].Expert Opin Inv Drug,2001,10(1):119-128.
[25]Gietema J,Veldhuis G,Guchelaar H,et al.Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer[J].Brit J Cancer,1995,71(6):1302.
[26]单鸿庞鹏飞.注射用洛铂在原収性肝癌TACE治疗中的专家共识[J].中华介入放射学电子杂志,2016,4(1):1-3.
[27]祝兴勇,张文萍,尤启冬.铂(Ⅱ)类抗肿瘤药物[J].化学迚展,2008,20(9):1324-1334.
[28]翁琳,陈凌亚.铂类釐属抗肿瘤药物的应用与研究迚展[J].中国药学杂志,2005,40(16):1205-1208.
[29]Di F A,Ruggiero A,Riccardi R.Cellular and molecular aspects of drugs of the future:oxaliplatin[J].CMLS-Cell Mol Life S,2002,59(11):1914-1927.
[30]Guo Z J,Sadler P J,Tsang S C.Immobilization and visualization of DNA and proteins on carbon nanotubes[J].Adv Mater,1998,10:701-703.
[31]Guo Z J,Murdoch P del S,Bednarski P J,et al.Electron-trans fer-driven Trans-Ligand Labilization:A novel activation mechani sm for Pt(IV)anticancer complexes[J].J Am Chem Soc,1998,120:8253-8254.
[32]Liu Q,Zhang J Y,Ke X K,et al.ESMS and NMR investigations on the interaction of the anticancer drug cisplatin and chemopreventive agent selenomethionine[J].J Chem Soc,Dalton Trans.2001,6(1):911-916.
[33]Reedijk J.Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?[J].Chem Rev,1999,99(9):2499-2510.
[34]贾木欣,刘恺,杨作银,等.抗癌药物cis-[Pt(NH3)(2-picoline)]2+与DNA加合的结构和成键特征[J].中国科学B,2003,33:474-481.
[35]Xiao H H,Qi R G,Liu S,Hu X L,Duan T C,Zheng Y H,Jing X B.Biodegradable polymer-cisplatin(IV)conjugate as a pro-drug of cisplatin(II)[J].Biomaterials,2011,32(30):7732-7739.
[36]Ho Y P,To K K,Auyeung S C,et al.Potential new antitumor agents from an innovative combination of demethylcantharidin,a modified traditional Chinese medicine,with a platinum moiety.[J].J Med Chem,2001,44(13):2065-2068.
[37]Liu X,Shen H,Zhu H,et al.In vitro cytotoxicity study on platinum(II)complexes with epoxysuccinates as leaving groups[J].Bioorg Med Chem Letter,2007,17(14):3831-3834.
[38]Zhang Y,Guo G,Ma B,et al.A hybrid platinum drug dichloroacetate-platinum(II)overcomes cisplatin drug resistance through dual organelle targeting[J].Anticancer Drugs,2015,26(7):698-705.
[39]Du R,Xiao H,Guo G,et al.Nanoparticle delivery of photosensitive Pt(IV)drugs for circumventing cisplatin cellular pathway and on-demand drug release[J].Colloids Surf B Biointerfaces,2014,123:734-741.
[40]Li W L,Zhang W J,Yang X Y,et al.Biodegradable polymersomes from four‐arm PEG‐b‐PDLLA for encapsulating hemoglobin[J].J Appl Poly Sci,2014,131(12):40433.
[41]Yang Q,Qi R,Cai J,et al.Biodegradable polymer-platinum drug conjugates to overcome platinum drug resistance[J].Rsc Advances,2015,5(101):83343-83349.
[42]张宇锋.重新确立药剂学的地位优先収展中国的辅料工业[J].中国新药杂志,2000,9(6):364-366.
[43]Kazunori K,Kwon G S,Masayuki Y,et al.Block copolymer micelles as vehicles for drug delivery[J].J Control Rel,1993,24(1-3):119-132.
[44]Yokoyama M,Inoue S,Kataoka K,et al.Preparation of adriamycin‐conjugated poly(ethylene glycol)‐poly(aspartic acid)block copolymer.A new type of polymeric anticancer agent[J].Macromolecular Rapid Communications,1987,8(9):431-435.
[45]Cabral H,Murakami M,Hojo H,et al.Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis[J].Pnas,2013,110(28):11397-11402.
[46]Gao Y,Jiang M,Ma Y Q,et al.Nanoparticle-mediated delivery of multinuclear platinum(IV)prodrugs with enhanced drug uptake and the activity of overcoming drug resistance[J].Anti-cancer drugs,2015,27(2):77-83.